Minoryx raises €21M series B, advances MIN-102

Minoryx Therapeutics S.L. (Mataro, Spain) raised €21.3 million ($24.7 million) on Sept. 26 in a series B round led by Fund+. SFPI, S.R.I.W. and Sambrinvest also participated as did existing investors Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity.

Minoryx's lead compound MIN-102 is in Phase II/III testing to treat adrenomyeloneuropathy with results expected in 2020. The compound is a PPAR γ agonist...